Gilead Sciences' Hepatitis Drug in Spotlight

Source: Minyanville, Brett Chase (4/20/12)

"Both medical and investor communities will scrutinize results from an experimental, next-generation treatment for the liver-destroying virus hepatitis C."

Minyanville, Brett Chase

It's just about showtime for Gilead Sciences Inc. (GILD:NASDAQ) and its experimental hepatitis C drug.

When specialist doctors from around the world gather in Spain next week to learn about new drugs in development for liver diseases, data for Gilead's GS-7977 will be closely scrutinized and among the most anticipated research presented. The company hopes to show it has a real potential winner of a drug to treat the liver-wasting virus hepatitis C.

The big medical meeting, the International Liver Conference, begins Wednesday, and some scientific abstracts have been released in advance of the five-day gathering. However, a pair of key studies for Gilead's drug are still embargoed until presentations starting Thursday. Gilead and a host of rivals are trying to develop an all-oral and better treatment regimen for hepatitis C. There has been a lot of excitement in the medical community and the investment world over Gilead's drug. . .View Full Article

Biotech Discovers Revolutionary Immunotherapy in Houston
Source: Jason Kolbert (04/24/2025)

Coya Therapeutics Inc. (COYA:NASDAQ) recently reported a statistically significant Treg improvement in FTD patients with its dual-action immunotherapy, showing promising neuroprotection, according to a D. Boral research note.

Biopharma Company Leverages AI-Powered Platform for Cancer Breakthroughs
Source: Streetwise Reports (04/24/2025)

Rakovina Therapeutics Inc. (RKV:TSX.V) announced its scientific advisor and collaborator Dr. Artem Cherkasov was recently recognized as a leader in AI-driven drug development. Find out which analysts recently initiated coverage on the company.

Analyst Reveals Undervalued Pharmaceutical Gem in Canada
Source: Dr. Douglas Loe (04/14/2025)

In a recent research note from Leede Financial Inc. analyst Dr. Douglas Loe said Theratechnologies Inc. (TH:TSX; THTX:NASDAQ) has long term potential.

Four-Year Data on New Drug for Early AD Positive
Source: Dr. Ram Selvaraju (04/09/2025)

Long-term treatment with this small molecule seems feasible given its safety and tolerability profile, noted an H.C. Wainwright & Co. report.

Rest of 2025 Rich With Catalysts for Immunotherapy Co.
Source: Jason Kolbert (04/09/2025)

These anticipated events will advance the oncology firm's lead candidate, for lung-only metastatic osteosarcoma, toward commercialization, noted a D. Boral Capital report.